Brind.
  1. Microsoft, Tevogen Bio Holdings Inc., and Databricks are collaborating to build the PredicTcell model for oncology applications.
  2. A partnership between Microsoft, Tevogen Bio Holdings Inc., Databricks, and Genmab was announced on August 23, 2025, accelerating therapeutic discovery and development.
  3. Microsoft, Tevogen Bio Holdings Inc., and Databricks are collaborating to build the PredicTcell model for oncology applications.
  4. A partnership between Microsoft, Tevogen Bio Holdings Inc., Databricks, and Genmab was announced on August 23, 2025, accelerating therapeutic discovery and development.

Microsoft, Tevogen Bio Holdings Inc., and Databricks are collaborating to build the PredicTcell model for oncology applications.

3 reports, 1 independent Updated Aug 6
Gone quiet
Reports
3
Developments
4
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Microsoft, Tevogen Bio Holdings Inc., and Databricks are collaborating to build the PredicTcell model for oncology applications.

Who's involved

What this event is mainly about
MicrosoftDatabricks

How it developed

Newest first. Tap a step to see who reported it.
  1. A partnership between Microsoft, Tevogen Bio Holdings Inc., Databricks, and Genmab was announced on August 23, 2025, accelerating therapeutic discovery and development.Sub-event
  2. The collaboration focuses on building the PredicTcell model for oncology.1 source
  3. Tevogen applauds NIST standards while continuing collaborations with Microsoft and Databricks.1 source
  4. The collaboration built the alpha version of the PredicTcell™ model for oncology applications.1 source

Keep exploring

Part of

A partnership between Microsoft, Tevogen Bio Holdings Inc., Databricks, and Genmab was announced on August 23, 2025, accelerating therapeutic discovery and development. All 1 developments

Within Microsoft, Tevogen Bio Holdings Inc., and Databricks are collaborating to build the PredicTcell model for oncology applications.

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireTevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology Tevogen.AI to explore external market opportunities as a po
  • GlobeNewswireTevogen.AI Applauds U.S. Government’s AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare WARREN, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings I
  • GlobeNewswireTevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development